Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Testosterone propionate
Drug ID BADD_D02173
Description Testosterone propionate is a slower-releasing anabolic steroid with a short half-life. It is a synthetic androstane steroid derivative of testosterone in the form of 17β propionate ester of testosterone.[T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974. Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160]
Indications and Usage Testosterone propionate is often used for muscle mass building. The original medical indication is for the treatment of androgen deficiency in male adults either in hypogonadism or andropause.[L1161] Nowadays testosterone propionate is indicated for its use in heifers in order to stimulate maximal growth.[L1160]
Marketing Status Discontinued
ATC Code G03BA03
DrugBank ID DB01420
KEGG ID D00959
MeSH ID D043343
PubChem ID 5995
TTD Drug ID Not Available
NDC Product Code 22552-0015; 52128-172; 64025-0019; 48087-0134; 51552-0030; 60870-0253; 30007-833; 62991-1412; 38779-0165; 0009-5123; 43647-789; 51927-1029; 49452-0011
Synonyms Testosterone Propionate | Testosteron Propionat Eifelfango | Eifelfango, Testosteron Propionat | Virormone | Agovirin
Chemical Information
Molecular Formula C22H32O3
CAS Registry Number 57-85-2
SMILES CCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Aggression19.05.01.001--Not Available
Alopecia23.02.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Anger19.04.02.001--Not Available
Anxiety19.06.02.002--
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.001--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site rash08.02.01.016; 23.03.13.008; 12.07.01.016--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Azoospermia21.03.03.001--
Blood testosterone decreased13.10.05.004--Not Available
Breast pain21.05.05.003--
Coagulopathy01.01.02.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 02.01.02.004; 17.02.05.003--
Dyspnoea02.01.03.002; 22.02.01.004--
Dysuria20.02.02.002--
Endocrine disorder05.09.01.001--Not Available
Epididymitis21.09.02.001; 11.01.19.005--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Gamma-glutamyltransferase increased13.03.01.011--
Gastrointestinal disorder07.11.01.001--Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages